S&S Healthcare (4198) reported revenue of NT$19.4 million for Oct 2026, +26.3% year on year and -8.7% from the previous month. Revenue for Jan–Oct 2026 was NT$149.2 million (-10.0% year on year).
In Oct 2026, it ranked No. 127 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$19.4 million | +26.3% | -8.7% |
| Sep 2026 | NT$21.2 million | +13.5% | +45.7% |
| Aug 2026 | NT$14.6 million | -3.2% | -31.2% |
| Jul 2026 | NT$21.2 million | +75.1% | +29.4% |
| Jun 2026 | NT$16.4 million | +92.3% | +108.5% |
| May 2026 | NT$7.8 million | -50.8% | -7.3% |
| Apr 2026 | NT$8.5 million | -38.5% | -35.2% |
| Mar 2026 | NT$13.1 million | -65.6% | +10.1% |
| Feb 2026 | NT$11.9 million | -14.5% | -22.3% |
| Jan 2026 | NT$15.3 million | +5.0% | -36.0% |
| Dec 2025 | NT$23.9 million | +97.4% | +64.1% |
| Nov 2025 | NT$14.5 million | -1.1% | -5.2% |
| Oct 2025 | NT$15.3 million | -49.5% | -17.9% |
| Sep 2025 | NT$18.7 million | +21.5% | +24.3% |
| Aug 2025 | NT$15 million | -40.1% | +24.4% |
| Jul 2025 | NT$12.1 million | -37.3% | +42.1% |
| Jun 2025 | NT$8.5 million | -55.1% | -46.7% |
| May 2025 | NT$15.9 million | -12.5% | +15.7% |
| Apr 2025 | NT$13.8 million | -19.4% | -63.7% |
| Mar 2025 | NT$38 million | +44.5% | +173.4% |
| Feb 2025 | NT$13.9 million | -52.9% | -4.6% |
| Jan 2025 | NT$14.6 million | -29.8% | +20.4% |
| Dec 2024 | NT$12.1 million | -44.5% | -17.8% |
| Nov 2024 | NT$14.7 million | -14.9% | -51.6% |
| Oct 2024 | NT$30.4 million | -25.3% | +97.4% |
Jan–Oct 2026 cumulative: NT$149.2 million (-10.0% YoY)
Other Biotech & Medical companies
Compare with peers: S&S Healthcare vs PEC / S&S Healthcare vs Lotus Pharm / S&S Healthcare vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16